AI drug company BenevolentAI revealed on Thursday that the data published in Eli Lilly's Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in COVID-19 patients.
On 4 February 2020, BenevolentAI researchers published the hypothesis of COV-BARRIER in The Lancet upon identification of Baricitinib as a potential treatment for COVID-19. The ACTT-2 clinical trial is reportedly the first AI-derived hypothesis for a COVID-19 treatment.
Based on COV-BARRIER trial, the US FDA granted emergency use authorisation (EUA) to Eli Lilly's baricitinib in combination with remdesivir to treat hospitalised COVID-19 patients. The trial in 1,525 hospitalised COVID-19 patients demonstrated baricitinib reduces mortality by 38%, showing the largest clinical effect reported to date for a reduction in mortality in this patient population.
Eli Lilly's COV-BARRIER study, baricitinib was given in addition to the standard of care, which included dexamethasone in the majority of patients. The trial did not meet statistical significance on the primary endpoint, a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation or death by day 28.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients